{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:20:50Z","timestamp":1740144050468,"version":"3.37.3"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T00:00:00Z","timestamp":1570492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Italian Ministry of Health","award":["RF- 2010-2320172"],"award-info":[{"award-number":["RF- 2010-2320172"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40259-019-00385-y","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T12:03:53Z","timestamp":1570622633000},"page":"55-64","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study"],"prefix":"10.1007","volume":"34","author":[{"name":"On behalf of the Italian Biosimilars Network (I-BioNetwork)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9549-6111","authenticated-orcid":false,"given":"Ylenia","family":"Ingrasciotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Belleudi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Trotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Addis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Fontana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Chinellato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Ientile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele Ugo","family":"Tari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Pastorello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Scondotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pasquale","family":"Cananzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Traversa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariangela","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-7296","authenticated-orcid":false,"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,8]]},"reference":[{"key":"385_CR1","unstructured":"Italian Association of Medical Oncology. Linee guida gestione della tossicit\u00e0 ematopoietica in oncologia. 2017. \nhttp:\/\/media.aiom.it\/userfiles\/files\/doc\/LG\/2017_LGAIOM_Toss_ematopoietica.pdf\n\n. Accessed 2 Oct 2019."},{"issue":"Suppl 3","key":"385_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1634\/theoncologist.13-S3-33","volume":"13","author":"MS Aapro","year":"2008","unstructured":"Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist. 2008;13(Suppl 3):33\u20136.","journal-title":"Oncologist."},{"issue":"6","key":"385_CR3","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JOP.2010.000132","volume":"6","author":"JD Rizzo","year":"2010","unstructured":"Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Somerfield MR, Temin S. American society of clinical oncology\/american society of hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Oncol Pract. 2010;6(6):317\u201320.","journal-title":"J Oncol Pract."},{"key":"385_CR4","unstructured":"European Medicines Agency. European public assessment reports. \nhttp:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter\n\n. Accessed 31 July 2019."},{"key":"385_CR5","unstructured":"Quintiles. The impact of biosimilar competition in Europe. Quintiles IMS. 2017. \nhttp:\/\/www.medicinesforeurope.com\/wp-content\/uploads\/2017\/05\/IMS-Biosimilar-2017_V9.pdf\n\n. Accessed 2 Oct 2019."},{"issue":"7","key":"385_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s40273-014-0163-9","volume":"32","author":"P Dylst","year":"2014","unstructured":"Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics. 2014;32(7):681\u201391.","journal-title":"Pharmacoeconomics."},{"issue":"3","key":"385_CR7","first-page":"129","volume":"8","author":"S Rompas","year":"2015","unstructured":"Rompas S, Goss T, Amanuel S, Coutinho V, Lai Z, Antonini P, et al. Demonstrating value for biosimilars: a conceptual framework. Am Health Drug Benefits. 2015;8(3):129\u201339.","journal-title":"Am Health Drug Benefits."},{"issue":"3","key":"385_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/14712598.2018.1410134","volume":"18","author":"G Trifir\u00f2","year":"2018","unstructured":"Trifir\u00f2 G, Marcian\u00f2 I, Ingrasciotta Y. Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. Expert Opin Biol Ther. 2018;18(3):309\u201315.","journal-title":"Expert Opin Biol Ther."},{"key":"385_CR9","unstructured":"European Medicines Agency (EMA). Biosimilars in the EU, Information guide for healthcare professionals. 2017. \nhttps:\/\/www.ema.europa.eu\/en\/documents\/leaflet\/biosimilars-eu-information-guide-healthcare-professionals_en.pdf\n\n. Accessed 2 Oct 2019."},{"key":"385_CR10","unstructured":"Agenzia Italiana del Farmaco (AIFA). Secondo position paper AIFA sui Farmaci Biosimilari. 2018."},{"key":"385_CR11","unstructured":"Agenzia Italiana del Farmaco (AIFA). L\u2019uso dei farmaci in Italia. Rapporto Nazionale anno 2017. 2018. \nhttp:\/\/www.aifa.gov.it\/sites\/default\/files\/Rapporto_OsMed_2017_AIFA.pdf\n\n. Accessed 2 Oct 2019."},{"issue":"4","key":"385_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-015-0132-7","volume":"29","author":"Y Ingrasciotta","year":"2015","unstructured":"Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, Tari DU, et al. How much are biosimilars used in clinical practice? A retrospective Italian population-based study of erythropoiesis-stimulating agents in the years 2009\u20132013. BioDrugs. 2015;29(4):275\u201384.","journal-title":"BioDrugs."},{"key":"385_CR13","unstructured":"Food and Drug Administration. Considerations in demonstrating interchangeability with a reference product guidance for industry. 2017. \nhttps:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM537135.pdf\n\n. Accessed 2 Oct 2019."},{"key":"385_CR14","unstructured":"European Medicines Agency (EMA). Committee for Medicinal Products for Human Use (CHMP): guideline on similar biological medicinal products. 2014. \nhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-similar-biological-medicinal-products-rev1_en.pdf\n\n. Accessed 2 Oct 2019."},{"issue":"2","key":"385_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2165\/11630770-000000000-00000","volume":"26","author":"C Loiacono","year":"2012","unstructured":"Loiacono C, Sgroi C, Coppolino S, Cannata A, Ferrara R, Arcoraci V. How much are biosimilars used in Southern Italy? A retrospective analysis of epoetin utilization in the local health unit of Messina in the years 2010\u20132011. BioDrugs. 2012;26(2):113\u201320.","journal-title":"BioDrugs."},{"issue":"1","key":"385_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40259-015-0155-0","volume":"30","author":"C D\u2019Amore","year":"2016","unstructured":"D\u2019Amore C, Da Cas R, Rossi M, Traversa G. Switching between epoetins: a practice in support of biosimilar use. BioDrugs. 2016;30(1):27\u201332.","journal-title":"BioDrugs."},{"issue":"4","key":"385_CR17","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/ndt\/gfk011","volume":"21","author":"F Locatelli","year":"2006","unstructured":"Locatelli F, Andrulli S, Memoli B, Maffei C, Del Vecchio L, Aterini S, et al. Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients. Nephrol Dial Transplant. 2006;21(4):991\u20138.","journal-title":"Nephrol Dial Transplant"},{"issue":"5 Suppl 3","key":"385_CR18","first-page":"S11","volume":"47","author":"KDOQI, National Kidney Foundation","year":"2006","unstructured":"KDOQI, National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47(5 Suppl 3):S11\u2013145.","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"385_CR19","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/1467-9868.00388","volume":"65","author":"JP Fine","year":"2003","unstructured":"Fine JP, Glidden DV, Lee KE. A simple estimator for a shared frailty regression model. J R Stat Soc Ser B Stat Methodol. 2003;65(1):317\u201329.","journal-title":"J R Stat Soc Ser B Stat Methodol."},{"key":"385_CR20","unstructured":"Agenzia Italiana del Farmaco (AIFA). Position paper sui farmaci biosimilari (28\/05\/2013). \nhttp:\/\/www.agenziafarmaco.gov.it\/sites\/default\/files\/AIFA_POSITION_PAPER_FARMACI_BIOSIMILARI.pdf\n\n. Accessed 2 Oct 2019."},{"issue":"1","key":"385_CR21","first-page":"59","volume":"75","author":"G Lonnemann","year":"2011","unstructured":"Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology\u2014a single-dialysis center experience. Clin Nephrol. 2011;75(1):59\u201362.","journal-title":"Clin Nephrol"},{"key":"385_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00845-y","author":"V Belleudi","year":"2019","unstructured":"Belleudi V, Trotta F, Addis A, et al. Italian Biosimilar Network (ItaBioNet). Effectiveness and safety of switching originator and biosimilar epoetins in patients with chronic kidney disease in a large-scale Italian cohort study. Drug Saf. 2019. \nhttps:\/\/doi.org\/10.1007\/s40264-019-00845-y\n\n.","journal-title":"Drug Saf."},{"issue":"7","key":"385_CR23","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2169\/internalmedicine.56.7455","volume":"56","author":"S Nagata","year":"2017","unstructured":"Nagata S, Ikegaya N, Ogino S, Uchida S, Itaya M, Momita A, et al. The resection of thyroid cancer was associated with the resolution of hyporesponsiveness to an erythropoiesis-stimulating agent in a hemodialysis patient with aceruloplasminemia. Intern Med. 2017;56(7):805\u201310.","journal-title":"Intern Med"},{"issue":"12","key":"385_CR24","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","volume":"363","author":"SD Solomon","year":"2010","unstructured":"Solomon SD, Uno H, Lewis EF, Eckardt K-U, Lin J, Burdmann EA, et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med. 2010;363(12):1146\u201355.","journal-title":"N Engl J Med"},{"issue":"1","key":"385_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2215\/CJN.01610407","volume":"3","author":"DT Gilbertson","year":"2008","unstructured":"Gilbertson DT, Ebben JP, Foley RN, Weinhandl ED, Bradbury BD, Collins AJ. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol. 2008;3(1):133\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"5","key":"385_CR26","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000169979","volume":"8","author":"P Gr\u00fctzmacher","year":"1990","unstructured":"Gr\u00fctzmacher P, Ehmer B, Limbach J, Messinger D, Kulbe KD, Scigalla P. Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism. Blood Purif. 1990;8(5):279\u201384.","journal-title":"Blood Purif"},{"issue":"5","key":"385_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0155805","volume":"11","author":"Y Ingrasciotta","year":"2016","unstructured":"Ingrasciotta Y, Giorgianni F, Marcian\u00f2 I, Bolcato J, Pirolo R, Chinellato A, et al. Comparative effectiveness of biosimilar, reference product and other erythropoiesis-stimulating agents (ESAs) still covered by patent in chronic kidney disease and cancer patients: an Italian population-based study. PLoS One. 2016;11(5):1\u201316.","journal-title":"PLoS One"},{"issue":"4","key":"385_CR28","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s40259-016-0175-4","volume":"30","author":"I Marcian\u00f2","year":"2016","unstructured":"Marcian\u00f2 I, Ingrasciotta Y, Giorgianni F, Bolcato J, Chinellato A, Pirolo R, et al. How did the introduction of biosimilar filgrastim influence the prescribing pattern of granulocyte colony-stimulating factors? Results from a multicentre, population-based study, from five Italian centres in the years 2009\u20132014. BioDrugs. 2016;30(4):295\u2013306.","journal-title":"BioDrugs."},{"key":"385_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3389\/fendo.2018.00095","volume":"9","author":"I Marcian\u00f2","year":"2018","unstructured":"Marcian\u00f2 I, Ingrasciotta Y, Giorgianni F, et al. Pattern of use of biosimilar and originator somatropin in italy: a population-based multiple databases study during the years 2009\u20132014. Front Endocrinol (Lausanne). 2018;9:95.","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"15","key":"385_CR30","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1200\/JCO.18.02142","volume":"37","author":"J Bohlius","year":"2019","unstructured":"Bohlius J, Bohlke K, Castelli R, Djulbegovic B, Lustberg MB, Martino M, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO\/ASH clinical practice guideline update. J Clin Oncol. 2019;37(15):1336\u201351. \nhttps:\/\/doi.org\/10.1200\/JCO.18.02142\n\n.","journal-title":"J Clin Oncol"},{"key":"385_CR31","unstructured":"Ministero della Salute, Agenzia Italiana del Farmaco (AIFA). Circolare AIFA del 3 agosto 2007. Linee guida per la classificazione e conduzione degli studi osservazionali sui farmaci. \nhttp:\/\/xoomer.virgilio.it\/pgiuff\/osservazionali.pdf\n\n. Accessed 14 Dec 2015."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00385-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-019-00385-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00385-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T23:20:21Z","timestamp":1602026421000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-019-00385-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,8]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1007\/s40259-019-00385-y","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"type":"print","value":"1173-8804"},{"type":"electronic","value":"1179-190X"}],"subject":[],"published":{"date-parts":[[2019,10,8]]},"assertion":[{"value":"8 October 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was conducted in the context of the finalized research project \u201cAssessment of Short and Long Term Risk\u2013Benefit Profile of Biologics through Healthcare Database Network in Italy\u201d (RF-2010-2320172), which was funded by the Italian Health Ministry. The financial assistance was used to access and analyze data from different partners.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Gianluca Trifir\u00f2 declares his participation in advisory boards on biosimilars, organized by Sandoz and Hospira; furthermore, he coordinates a pharmacoepidemiology research team at the University of Messina, which receives research grants for projects that are not related to the topic of the paper. Ylenia Ingrasciotta, Valeria Belleudi, Francesco Trotta, Antonio Addis, Andrea Fontana, Alessandro Chinellato, Valentina Ientile, Daniele Ugo Tari, Giuseppe Roberto, Maurizio Pastorello, Salvatore Scondotto, Pasquale Cananzi, Giuseppe Traversa, Marina Davoli, and Mariangela Rossi declare that they have no conflicts of interest that might be relevant to the contents of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in the context of the \u201cAssessment of Short and Long Term Risk\u2013Benefit Profile of Biologics through Healthcare Database Network in Italy\u201d project, funded by the Italian Ministry of Health. The study protocol was notified to the Ethical Committee of the Academic Hospital of Messina [], according to the current national law. The manuscript does not contain clinical studies or patient data. For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}